We are monitoring the impact of COVID-19 on Latin America Biosimilars Market Get in touch with us for detailed analysis Know More
Share on

Latin America Biosimilars Market Research Report – Segmented By Type, Technology, Application, Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis on Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1082
Pages: 145

Latin America Biosimilars Market Size (2022 to 2027)

As per our analysis, the Latin America Biosimilars Market size is predicted to grow from USD 1.21 billion in 2022 and is estimated to be growing at a CAGR of 29.68%, to reach USD 4.42 billion by 2027.

The Latin American market is driven by factors including the increasing prevalence of chronic disorders like cancer and diabetes, complementing the growing demand for pharmaceutical drugs, especially for high-priced proprietary medicines. Biosimilars are characterized as the most important market in the healthcare sector. Biosimilars are seen as a budget-effective treatment option with increasing healthcare costs. In addition, biosimilars can be used effectively to diagnose and treat several different chronic conditions like diabetes, cancers, renal failure, etc. Demand for biosimilars is projected to rise in the next few years.

Market growth, although, is constrained by the reference product’s massive cost, which raises the financial burden on patients and service providers for reimbursement. Due to the drop in demand, the lack of economies of scale is a factor behind such high costs. In addition, the growth of the biosimilar market is hindered by the lack of regulatory guidelines, consumer brand preferences, physician’s reluctance to implement biosimilars, and the large capital needed for research and development.

The drop in biosimilar prices is expected to have a massive impact on biosimilar’s total sales, and patients will continue always to be the main beneficiaries. A recent and continuing trend among manufacturers focused on rising biosimilar markets in Latin America is the drop in the innovator's price with huge discounts. Furthermore, biosimilar manufacturers are likely to approach multiple productions or quantities of production at different levels. Throughout the forecast period, the potential profitability of producing several biosimilar products in the same facility may provide a favorable opportunity for growth for manufacturing firms. Several market players are gradually subcontracting the manufacture of biosimilar goods. These two technologies are projected in the coming years to support the regional market.

This research report on the Latin America biosimilars market has been segmented and sub-segmented the market into the following categories:

By Product Type:

  • Protein
  • Insulin
  • Human Growth Hormones
  • Granulocyte Colony-stimulating Factor (G-CSF)
  • Interferons
  • Recombinant Glycosylated Proteins
  • Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Recombinant Peptides
  • Glucagon

By Technology:

  • Mass Spectroscopy
  • Chromatography
  • Monoclonal Antibody Technology
  • Recombinant DNA Technology
  • Nuclear Magnetic resonance (NMR) technology
  • Electrophoresis
  • Bioassay

By Disease:

  • Oncology Diseases
  • Blood Disorders
  • Growth hormone deficiencies
  • Chronic and autoimmune diseases
  • Others

By Country: 

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Regionally, Biosimilars in Latin America account for a large percentage of pharmaceutical expenditure and relatively small prescriptions. In many Latin American countries, biosimilars for breast cancer, rheumatoid arthritis, and non-small cell lung cancer are presently being developed. They may soon be out in the market.

The Brazilian biosimilars market is estimated to be the most lucrative regional market in Latin America during the forecast period. The Brazilian government presents biological drugs through the programs, which represents an important portion of accounts for the health sector. However, biological drugs represent only 2% of the drugs dispensed by the government and the rest 41% of the complete amount spent by the Ministry of Health. Therefore, the government is also striving to grow the possibility of bio-similar that allow the authorization of the market of the medicines.

The Mexican Biosimilars Market is forecasted to showcase a healthy CAGR from 2022 to 2027. In Mexico, nearly 40% of the patients with cancer types are qualified for the biological tests those who do not receive the therapy. Therefore, the Mexico market represents an important opportunity to help affordable and widen access to provide standard treatment for patients. Mexican health authorities related to the necessary scientific proof needed to examine the efficacy and protection of biosimilar drugs post and pre-arrival into the market of Mexico.

Key market participants in the Latin American Biosimilars market profiled in this report are Sandoz International GmbH, Wockhardt Ltd, Hospira, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy’s Laboratories, Biocon Limited, Mylan, Inc., Zydus Cadila, Celltrion Inc., Roche Diagnostics and Cipla Ltd.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Protein     

                                5.1.2 Insulin       

                                5.1.3 Human Growth Hormones

                                5.1.4 Granulocyte Colony-stimulating Factor (G-CSF)       

                                5.1.5 Interferons             

                                5.1.6 Recombinant Glycosylated Proteins             

                                5.1.7 Erythropoietin       

                                5.1.8 Monoclonal Antibodies     

                                5.1.9 Follitropin

                                5.1.10 Recombinant Peptides    

                                5.1.11 Glucagon               

                                5.1.12 Calcitonin              

                5.2 By Technology                          

                                5.2.1 Mass Spectroscopy             

                                5.2.2 Chromatography  

                                5.2.3 Monoclonal Antibody Technology

                                5.2.4 Recombinant DNA Technology       

                                5.2.5 Nuclear magnetic resonance (NMR) technology     

                                5.2.6 Electrophoresis     

                                5.2.7 Bioassay   

                5.3 By Application                           

                                5.3.1 Oncology diseases

                                5.3.2 Blood disorders    

                                5.3.3 Growth hormone deficiencies        

                                5.3.4 Chronic and autoimmune diseases

                                5.3.5 Others      

6. Geographical Analysis                                              

                                6.1 Introduction              

                                6.2 Brazil             

                                6.3 Mexico         

                                6.4 Rest of Latin America             

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Sandoz International GmbH                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Wockhardt                 

                8.3 Hospira                        

                8.4 Teva Pharmaceutical Industries                         

                8.5 Dr. Reddy’s Laboratories                      

                8.6 Biocon                          

                8.7 Mylan                           

                8.8 Zydus Cadila                               

                8.9 Celltrion                       

                8.10 Roche Diagnostics                 

                8.11 Cipla                            

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

                                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Latin America Biosimilars Market, By Type, From 2022 - 2027 (USD Million)
  2. Latin America Protein Market, By Region, From 2022 - 2027 (USD Million)
  3. Latin America Insulin Market, By Region, From 2022 - 2027 (USD Million)
  4. Latin America Human Growth Hormones Market, By Region, From 2022 - 2027 (USD Million)
  5. Latin America Granulocyte Colony-stimulating Factor (G-CSF) Market, By Region, From 2022 - 2027 (USD Million)
  6. Latin America Interferons Market, By Region, From 2022 - 2027 (USD Million)
  7. Latin America Recombinant Glycosylated Proteins Market, By Region, From 2022 - 2027 (USD Million)
  8. Latin America Erythropoietin Market, By Region, From 2022 - 2027 (USD Million)
  9. Latin America Monoclonal Antibodies Market, By Region, From 2022 - 2027 (USD Million)
  10. Latin America Follitropin Market, By Region, From 2022 - 2027 (USD Million)
  11. Latin America Recombinant Peptides Market, By Region, From 2022 - 2027 (USD Million)
  12. Latin America Glucagon Market, By Region, From 2022 - 2027 (USD Million)
  13. Latin America Calcitonin Market, By Region, From 2022 - 2027 (USD Million)
  14. Latin America Biosimilars Market, By Technology, From 2022 - 2027 (USD Million)
  15. Latin America Mass Spectroscopy Market, By Region, From 2022 - 2027 (USD Million)
  16. Latin America Chromatography Market, By Region, From 2022 - 2027 (USD Million)
  17. Latin America Monoclonal Antibody Technology Market, By Region, From 2022 - 2027 (USD Million)
  18. Latin America Recombinant DNA Technology Market, By Region, From 2022 - 2027 (USD Million)
  19. Latin America Nuclear magnetic resonance (NMR) technology Market, By Region, From 2022 - 2027 (USD Million)
  20. Latin America Electrophoresis Market, By Region, From 2022 - 2027 (USD Million)
  21. Latin America Bioassay Market, By Region, From 2022 - 2027 (USD Million)
  22. Latin America Biosimilars Market, By Application, From 2022 - 2027 (USD Million)
  23. Latin America Oncology diseases Market, By Region, From 2022 - 2027 (USD Million)
  24. Latin America Blood disorders Market, By Region, From 2022 - 2027 (USD Million)
  25. Latin America Growth hormone deficiencies Market, By Region, From 2022 - 2027 (USD Million)
  26. Latin America Chronic and autoimmune diseases Market, By Region, From 2022 - 2027 (USD Million)
  27. Latin America Others Market, By Region, From 2022 - 2027 (USD Million)
  28. Brazil Biosimilars Market, By Type, From 2022 - 2027 (USD Million)
  29. Brazil Biosimilars Market, By Technology, From 2022 - 2027 (USD Million)
  30. Brazil Biosimilars Market, By Application, From 2022 - 2027 (USD Million)
  31. Rest of Latin America Biosimilars Market, By Type, From 2022 - 2027 (USD Million)
  32. Rest of Latin America Biosimilars Market, By Technology, From 2022 - 2027 (USD Million)
  33. Rest of Latin America Biosimilars Market, By Application, From 2022 - 2027 (USD Million)

 

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample